Skip to main content
. Author manuscript; available in PMC: 2015 Jan 28.
Published in final edited form as: Melanoma Res. 2014 Apr;24(2):150–157. doi: 10.1097/CMR.0000000000000050

Fig. 6.

Fig. 6

Overall survival (OS) by autoimmunity at 1-year landmark time among stage III patients treated with high-dose interferon in E1694. There was a trend toward improved OS in patients who developed autoimmunity (hazard ratio=0.80, 95% confidence interval: 0.50–1.98; P=0.33).